OPEN END TURBO BULL OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Delayed Deutsche Boerse AG 12:29:30 2024-06-21 pm EDT | ||
| 18.18 EUR | -2.21% |
|
| Current month | +11.72% | ||
| 1 month | +13.70% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-21 | 18.18 | -2.21% |
| 24-06-20 | 18.59 | +2.09% |
| 24-06-19 | 18.21 | -1.89% |
| 24-06-18 | 18.56 | -3.28% |
| 24-06-17 | 19.19 | -3.08% |
Delayed Quote Deutsche Boerse AG
Last update June 21, 2024 at 12:29 pm EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
UniCredit
|
| WKN | HC41QE |
| ISIN | DE000HC41QE8 |
| Date issued | 2023-02-10 |
| Strike | 271.9 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 5.26 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 19.9 € |
|---|---|
| Lowest since issue | 4.37 € |
| Spread | 0.03 € |
| Spread % | 0.16% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
471.4
USD
Average target price
463.4
USD
Spread / Average Target
-1.69%
- Stock Market
- Certificates
- Certificat
